Adaptimmune and TCR2 Merge to Form a Solid Tumour Company
By Shweta Gupta & Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 3 (Table of Contents)
Published: 28 Mar-2023
DOI: 10.3833/pdr.v2023.i3.2775 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In an all-stock transaction, Adaptimmune Therapeutics will merge with TCR2 Therapeutics to create a preeminent cell therapy company focused on treating solid tumours...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS